Dr. Wei Zhang
My Social Links

Dr. Wei Zhang

Professor
Central South University, China

Highest Degree
Ph.D. in Pharmacology from Central South University, China

Share this Profile

Area of Interest:

Pharmacology and Toxicology
100%
Clinical Pharmacology
62%
Drug Assay
90%
Alternative Medicine
75%
Chromatography
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Luo, J.Q., L.Y. Wang, F.Z. He, N.L. Sun and G.F. Tang et al., 2013. Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment. Pharmacogenomics,. .
    Direct Link  |  
  2. Li, X., F.M. Lian, D. Guo, L. Fan and J. Tang et al., 2013. The rs1142345 in TPMT affects the therapeutic effect of traditional hypoglycemic herbs in prediabetes. Evid Based Complement Altern. Med., Vol. 2013. 10.1155/2013/327629.
    CrossRef  |  
  3. Li, H., W. Zhang and H. Zhou, 2013. Electrochemical biosensor based on base stacking-dependent DNA hybridization assay for protein detection. Anal. Biochem., 10.1016/j.ab.2013.12.019.
    CrossRef  |  
  4. He, F.Z., H.L. McLeod and W. Zhang, 2013. Current pharmacogenomic studies on hERG potassium channels. Trends Mol. Med., 19: 227-238.
    CrossRef  |  
  5. He, F., J. Luo, Z. Luo, L. Fan and Y. He et al., 2013. The KCNH2 genetic polymorphism (1956, C>T) is a novel biomarker that is associated with CCB and α,β-ADR blocker response in EH patients in China. PLoS One, Vol. 8. 10.1371/journal.pone.0061317.
    CrossRef  |  
  6. Chen, Y., W. Zhang, W.H. Huang, Z.R. Tan, Y.C. Wang, X. Huang and H.H. Zhou, 2013. Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers. Eur. J. Clin. Pharmacol., 69: 1933-1938.
    CrossRef  |  
  7. Chen, W.Q., Y. Shu, Q. Li, L.Y. Xu and W.R. Mary et al., 2013. Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan. PLoS One, Vol. 8. 10.1371/journal.pone.0070341.
    CrossRef  |  
  8. Zhang, W., T.Y.K. Chan, L. Fan, Y. Guo and H.H. Zhou, 2012. Translating pharmacogenomics into personalized medicine and drug development. Pers. Med., 9: 93-97.
    CrossRef  |  
  9. Zhang, W., M.W. Roederer, W.Q. Chen, L. Fan and H.H. Zhou, 2012. Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics, 13: 223-231.
    CrossRef  |  
  10. Wu, L.X., C.X. Guo, W.Q. Chen, G. Wang and L. Fan et al., 2012. Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: An in vitro and in vivo assessment. Br. J. Clin. Pharmacol., 73: 750-757.
    CrossRef  |  
  11. Wu, L.X., C.X. Guo, Q. Qu, J. Yu and W.Q. Chen et al., 2012. Effects of natural products on the function of human organic anion transporting polypeptide 1B1. Xenobiotica, 42: 339-348.
    CrossRef  |  
  12. Qin, W.J., W. Zhang, Z.Q. Liu, X.P. Chen and Z.R. Tan et al., 2012. Rapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men. Br. J. Clin. Pharmacol., 74: 999-1004.
    CrossRef  |  
  13. Guo, C.X., Q. Pei, J.Y. Yin, X.D. Peng and B.T. Zhou et al., 2012. Effects of Ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices. Xenobiotica, 42: 784-790.
    CrossRef  |  
  14. Cao, S., G. Zhou, D.S.O. Yang, H. Wu and K. Xiao et al., 2012. Pharmacokinetic interactions between ilaprazole and clarithromycin following ilaprazole, clarithromycin and amoxicillin triple therapy. Acta Pharmacol. Sin., 33: 1095-1100.
    CrossRef  |  Direct Link  |  
  15. Roederer, M.W., F. Sanchez-Giron, K. Kalideen, W. Kudzi, H.L. McLeod and W. Zhang, 2011. Pharmacogenetics and rational drug use around the world. Pharmacogenomics, 12: 897-905.
    CrossRef  |  Direct Link  |  
  16. Fan, L., G. Zhou, D. Gou, Y.L. Liu and W.Q. Chen et al., 2011. The pregnane X receptor agonist St John's wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide. Clin. Pharmacolkinet, 50: 605-611.
    CrossRef  |  
  17. Zhou, G., S. Shi, W. Zhang, Z. Tan and Y. Chen et al., 2010. Identification of ilaprazole metabolites in human urine by HPLC-ESI-MS/MS and HPLC-NMR experiments. Biomed. Chromatogr., 24: 1130-1135.
    CrossRef  |  
  18. He, Y.J., W. Zhang, Y. Chen, D. Guo and J.H. Tu et al., 2009. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin. Chim. Acta, 405: 49-52.
    CrossRef  |  
  19. Zhang, W., S. Deng, X.P. Chen, G. Zhou and H.T. Xie et al., 2008. Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: A randomized, single-blind, placebo-controlled, crossover study. Clin. Ther., 30: 1283-1289.
    Direct Link  |  
  20. Li, Y., W. Zhang, D. Guo, G. Zhou, H. Zhou and Z. Xiao, 2008. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clin. Chim. Acta, 391: 60-67.
    CrossRef  |  
  21. He, Y.J., W. Zhang, J.H. Tu, J. Kirchheiner and Y. Chen et al., 2008. HNF1a inhibitor ursodeoxycholic acid (UDCA) influences pharmacokinetics of the OATP1B1 substrate rosuvastatin and bilirubin. Drug Metab. Dispos., 36: 1453-1456.
  22. Chen, B.L., W. Zhang, Q. Li, Y.L. Li and Y.J. He et al., 2008. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms. Clin. Exp. Pharmacol. Physiol., 35: 904-908.
    CrossRef  |  
  23. Zhang, W., Y.J. He, G. Zhou, L. Fan and Q. Li et al., 2007. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation. Clin. Exp. Pharmacol. Physiol., 34: 1240-1244.
    CrossRef  |  
  24. Fan, L., W. Zhang, D. Gou, Z.R. Tan and P. Xu et al., 2007. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1. Clin. Pharmacol. Ther., 28: 1685-1692.
  25. Zhang, W., Y.J. He, C.T. Han, Z.Q. Liu and Q. Li et al., 2006. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br. J. Clin. Pharmacol., 62: 567-572.
    Direct Link  |  
  26. Zhang, W., B.N. Yu, Y.J. He, L. Fan and Q. Li et al., 2006. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta, 373: 99-103.
    CrossRef  |  
  27. Zhang, W., B.L. Chen, V. Ozdemir, Y.J. He and G. Zhou et al., 2006. SLCO1B1 521T→C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br. J. Clin. Pharmacol., 64: 346-352.
    CrossRef  |  
  28. Liu, Y.L., W. Zhang, Z.R. Tan, D.S. Ouyang and C.H. Luo et al., 2006. Metabolisms of lornoxicam and its major metabolite 5'-hydroxy lornoxicam related to CYP2C9 Genotype in healthy subjects. Clin. Chim. Acta, 364: 287-291.